Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy

Scholar Rock NASDAQ:SRRK shares continued to tumble on Tuesday as Barclays downgraded the Massachusetts-area biotech despite last week’s FDA approval of its lead asset, Isembyld, for spinal muscular atrophy, a rare neuromuscular disorder.Despite a 7% YTD gain, Scholar Rock NASDAQ:SRRK has lost more…